Pulse nav.journalClub Debates activos Tendencias Explorar Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

© Synapse Social LLC, 2026

Política de privacidad

Inicio Explorar nav.journalClub Tendencias

⌘+K

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma | Synapse

October 4, 2017Open Access

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Obinutuzumab-based immunochemotherapy and maintenance therapy resulted in longer progression-free survival than rituximab-based therapy. High-grade adverse events were more common with obinutuzumab-based chemotherapy. (Funded by F. Hoffmann-La Roche; GALLIUM ClinicalTrials.gov number, NCT01332968 .).

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Marcus et al. (Wed,) studied this question.

synapsesocial.com/papers/69d6fca28dca315383ed96ce https://doi.org/https://doi.org/10.1056/nejmoa1614598

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo